Dr. Laura van ‘t Veer has a 25-year track record in molecular oncology research and over 280 scientific publications. She is chair of the AACR Diagnostic Policy committee and chair of the Scientific Advisory Committee of the National Biomarker Development Alliance and has received the European Society Medical Oncology (ESMO) Lifetime Achievement Award for Translational Research in Breast Cancer in 2007, the 2014 European Union Prize for Women Innovators and the EPO European Inventor Award in 2015. In 2017, she received the European CanCer Organization (ECCO) Clinical Research Award. Last year, she was recognized by 24/7 Wall Street as one of ’32 Amazing Women Inventors’.
Dr. van ‘t Veer holds a PhD in Medicine from the University of Leiden and held several positions at the Cancer Center of Harvard Medical School, Massachusetts General Hospital in Boston and The Netherlands Cancer Institute where she headed the Diagnostic Oncology department. She is Professor of Laboratory Medicine at UCSF since 2010.
Dr. van ‘t Veer is best known for work that originated at Netherlands Cancer Institute (NKI) on a 70-gene activity signature which distinguishes whether breast cancer has a low or high risk of recurrence. This was the basis for the MammaPrint® test (Agendia, co-founded by Dr van’t Veer). MammaPrint® obtained clearance from the FDA in 2007 and is included in many national and international guidelines. Her current research focus is personalized oncology by optimized biomarker – targeted dug matching, including her work as Biomarker Chair of the I-SPY 2 TRIAL.